Two scientific studies have found that the Medtronic Infuse Bone Graft may increase risks and not be any more beneficial than current procedures. Both studies were published in the Annals of Internal Medicine and found that the Infuse Bone Graft did not improve pain or function, but did pose additional risks, including cancer.
Medtronic paid to have the studies conducted after doctors began questioning the integrity of previous studies lauding the device’s efficacy. The use of the Infuse by surgeons has decreased significantly after stories of Infuse Bone Graft side effects began spreading through the medical community.
When inserted via unapproved methods, severe Infuse Bone Graft complications can occur, including excess bone growth, paralysis and retrograde ejaculation. Medtronic is facing several Infuse Bone Graft lawsuits alleging that the company illegally promoted off-label, or unapproved, usage of the device.